MindBio Therapeutics Corp. rose 29.4% on Thursday, November 12, 2026, on 33,103 shares, 2.6 times its average daily volume. No headline about MBIO came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
MindBio Therapeutics Corp. (MBIO:CSE) closed at $0.110 on November 12, 2026, up 29.41% on the day. The stock trades 97.2% below its 52-week high of $3.99 and 46.7% above its 52-week low of $0.075. Over the past year, it lost 91.5%. MindBio Therapeutics Corp. is part of the Life Sciences sector.
In 252 trading sessions since November 12, 2025, MBIO closed higher on 70 days (28%). Its best day was December 1, 2025 (+80.68%) and its worst was December 15, 2025 (-60.61%). The stock moved 10% or more in a single session 54 times. It opened at least 5% above the previous day's high 16 times.
MindBio Therapeutics Corp. operates as a clinical stage drug development company. It is involved in the clinical research into the microdosing of psychedelic medicines to treat a range of medical conditions, such as depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. The company is based in Melbourne, Australia.
Find more stocks like MBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.